Raymond James & Associates Invests $137,000 in Ampio Pharmaceuticals, Inc. (AMPE) Stock

Raymond James & Associates acquired a new stake in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 33,630 shares of the specialty pharmaceutical company’s stock, valued at approximately $137,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AMPE. Geode Capital Management LLC boosted its stake in Ampio Pharmaceuticals by 101.9% in the fourth quarter. Geode Capital Management LLC now owns 487,410 shares of the specialty pharmaceutical company’s stock valued at $1,983,000 after acquiring an additional 246,040 shares during the period. Brandes Investment Partners LP acquired a new position in Ampio Pharmaceuticals in the fourth quarter valued at approximately $204,000. Virtu Financial LLC boosted its stake in Ampio Pharmaceuticals by 787.5% in the fourth quarter. Virtu Financial LLC now owns 92,344 shares of the specialty pharmaceutical company’s stock valued at $376,000 after acquiring an additional 81,939 shares during the period. Wells Fargo & Company MN boosted its stake in Ampio Pharmaceuticals by 113.7% in the fourth quarter. Wells Fargo & Company MN now owns 40,671 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 21,638 shares during the period. Finally, Carnick & Kubik Group LLC boosted its stake in Ampio Pharmaceuticals by 46.2% in the fourth quarter. Carnick & Kubik Group LLC now owns 205,481 shares of the specialty pharmaceutical company’s stock valued at $836,000 after acquiring an additional 64,914 shares during the period.

Shares of NYSEAMERICAN AMPE opened at $2.78 on Friday. Ampio Pharmaceuticals, Inc. has a 12-month low of $0.38 and a 12-month high of $4.95.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.

Want to see what other hedge funds are holding AMPE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE).

Institutional Ownership by Quarter for Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply